Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044104 | 1.00 | ACHE (0.57) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL22550766 | 0.80 | ACHE (0.64) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL11608460 | 0.78 | ACHE (0.62) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL11608464 | 0.78 | ACHE (0.62) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL17899562 | 0.78 | DRD3 (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL9305014 | 0.78 | MAPT (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL22822883 | 0.78 | MAPT (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL9305010 | 0.78 | MAPT (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL22550769 | 0.75 | CYP1A2 (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 | |
| SCHEMBL8372688 | 0.75 | CYP1A2 (0.66) | ACHEBCHEHTTMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368975-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR HIGH-FIDELITY CAS13A VARIANTS WITH IMPROVED SPECIFICITY | UNIVERSITY OF ROCHESTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-12419879-B2 | Combination therapy for the treatment of pancreatic cancer | GENENTECH, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250018038-A1 | SURVIVIN TARGETING POLYPEPTIDES FOR DETECTION AND TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2025-01-16 | — | — | US | disclosed |
| US-12005073-B2 | Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230405124-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. | 2023-12-21 | — | — | US | disclosed |
| EP-4274605-A1 | INDINAVIR BASED CHEMICAL DIMERIZATION T CELL ENGAGER COMPOSITIONS | TigaTX, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116808219-A | Gamma secretase modulators for the treatment of immune system dysfunction | 安可初克公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3503922-B1 | COMBINATION THERAPY FOR THE TREATMENT OF PANCREATIC CANCER | GENENTECH INC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022150792-A1 | INDINAVIR BASED CHEMICAL DIMERIZATION T CELL ENGAGER COMPOSITIONS | SOTERIA BIOTHERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11320422-B2 | Inhibition of protein degradation for improved production | LONZA LTD. (CH) | 2022-05-03 | — | — | US | disclosed |
| US-11286482-B2 | Endosomal cleavable linkers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419879-B2 | Combination therapy for the treatment of pancreatic cancer | JAK2, STAT3, STAT6 | ACHE 4781/4885BCHE 4305/4885HTT 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.